{
  "content": "Diagnosis\n\t1. Transverse colon adenocarcinoma with neuroendocrine features\n\tDate of diagnosis\n\tJanuary 2024\n\n\tTreatment aim\n\tPalliative\n\n\tSummary of completed treatment and relevant dates\n\n\tSurgery\n\t15 Jan 2024 Extended right hemicolectomy\n\n\tChemotherapy\n\t1. FOLFOX from Feb 2024 - discontinued after 2 cycles due to progression\n\t2. FOLFIRI + Bevacizumab commenced March 2024\n\n\tClinical studies\n\tNot eligible\n\n\tCurrent disease status\n\tProgressive disease in liver, stable lung metastases\n\n\tCurrent issues\n\tGrade 3 neutropenia, Grade 2 diarrhea\n\n\tSummary of consultation\n\tReviewed today prior to cycle 4 FOLFIRI/Bevacizumab. Recent CT shows mixed response with reduction in size of largest liver lesion (segment 7, now 4.2cm from 5.8cm) but new satellite lesions. Lung metastases stable. Performance status remains 2. Experiencing ongoing diarrhea grade 2 despite loperamide. Latest bloods show neutropenia (ANC 0.8) requiring GCSF support. CEA rising from 245 to 380.\n\n\tFurther investigations\n\tRepeat CT chest/abdomen/pelvis after cycle 6\n\n\tMedication prescribed\n\tFilgrastim 300mcg daily for 5 days\n\n\tFollow up\n\tNext oncology follow up in 2 weeks pre cycle 5\n\n\tRequired GP actions\n\tWeekly FBC monitoring\n\n\tSummary of information given to patient\n\tDiscussed mixed response to treatment and options for dose modification due to toxicity. Plan to continue at current dose with enhanced supportive care.",
  "output": {
    "primary_cancer": {
      "site": "transverse colon",
      "year": 2024,
      "month": 1,
      "metastases": "liver and lung metastases",
      "histopathology_status": "adenocarcinoma with neuroendocrine features",
      "biomarker_status": "MSS, KRAS G12V mutation",
      "cancer_timeline": [
        {
          "type": "treatment_surgery",
          "value": "Extended right hemicolectomy",
          "year": 2024,
          "month": 1
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started FOLFOX chemotherapy",
          "year": 2024,
          "month": 2
        },
        {
          "type": "treatment_systemic_change",
          "value": "Discontinued FOLFOX after 2 cycles due to disease progression",
          "year": 2024,
          "month": 3
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started FOLFIRI + Bevacizumab",
          "year": 2024,
          "month": 3
        },
        {
          "type": "laboratory_finding",
          "value": "CEA rising from 245 to 380",
          "year": 2024,
          "month": null
        },
        {
          "type": "anatomical_finding",
          "value": "CT shows mixed response with reduction in largest liver lesion to 4.2cm from 5.8cm but new satellite lesions, stable lung metastases",
          "year": 2024,
          "month": null
        }
      ]
    },
    "patient_facts": [
      {
        "type": "performance_status",
        "value": "Performance status 2"
      },
      {
        "type": "current_symptom",
        "value": "Grade 2 diarrhea despite loperamide"
      },
      {
        "type": "investigation_finding",
        "value": "Neutropenia with ANC 0.8"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "Metastatic colon cancer showing mixed response to second-line FOLFIRI/Bevacizumab with significant treatment toxicities"
      },
      {
        "type": "latest_treatment_response",
        "value": "Mixed response with shrinkage of largest liver lesion but new satellite lesions, stable lung metastases"
      },
      {
        "type": "latest_treatment_toxicity",
        "value": "Grade 3 neutropenia requiring GCSF support and persistent grade 2 diarrhea"
      },
      {
        "type": "update_to_treatment",
        "value": "Continuing current dose FOLFIRI/Bevacizumab with enhanced supportive care"
      },
      {
        "type": "planned_investigation",
        "value": "Repeat CT chest/abdomen/pelvis after cycle 6"
      },
      {
        "type": "follow_up_referral",
        "value": "Review in 2 weeks pre cycle 5"
      }
    ]
  }
}